Kancera AB (Publ) - KNCQF

Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company develops drugs for the treatment of leukemia and solid tumors based on blocking survival signals in the cancer cell and on preventing adaptation of the cancer’s metabolism. Its drug development projects include ROR inhibitors for the treatment of leukemia and solid tumors; PFKFB inhibitors for reducing cancer’s energy supply from glucose to solid tumors; histone deacetylases6 inhibitors that are aimed to neutralize blood cancer by controlling the cancer cell genome; and AZD8797 Fractalkine inhibitors for stopping the tumor growth and relieving severe pain, as well as small molecule inhibitors of epigenetic processes in parasites for the development of various treatments, including malaria and schistosomiasis. Kancera AB (Publ) has a partnership with Recipharm AB to develop and manufacture KAND567, a pharmaceutical candidate that counteracts the onset of autoimmune disorders, as well as neuritis and pain in connection with chemotherapy against cancer. The company was founded in 2010 and is based in Solna, Sweden.